Marshall Wace’s Soleno Therapeutics SLNO Stock Holding History

Marshall Wace’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-221,214	Closed	-$7.41M	–	3687
2026 Q1	$7.41M	Buy	221,214 +214,619	+3,254%	+$8.41M	0.01%	1112
2025 Q4	$305K	Sell	6,595 -177,633	-96%	-$9.74M	﹤0.01%	2447
2025 Q3	$12.5M	Sell	184,228 -104,106	-36%	-$7.72M	0.01%	838
2025 Q2	$24.2M	Buy	288,334 +164,580	+133%	+$12.3M	0.03%	517
2025 Q1	$8.84M	Sell	123,754 -276,095	-69%	-$13.4M	0.01%	815
2024 Q4	$18M	Buy	399,849 +152,010	+61%	+$7.88M	0.02%	584
2024 Q3	$12.5M	Buy	+247,839	New	+$11.9M	0.02%	675
2024 Q2	–	Sell	-176,237	Closed	-$7.54M	–	2919
2024 Q1	$7.54M	Buy	+176,237	New	+$7.97M	0.01%	843

Marshall Wace's SLNO Position: Q2 2026 in Review

Marshall Wace sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 221,214 shares — an estimated $7.41M sold.

Marshall Wace first reported a position in SLNO in Q1 2024 and held it in 8 quarters. The position peaked at $24.2M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Marshall Wace reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 221,214 Soleno Therapeutics shares in Q2 2026, an estimated $7.41M.
Marshall Wace first reported a position in Soleno Therapeutics in Q1 2024 and held it in 8 quarters.
Marshall Wace's Soleno Therapeutics position peaked at $24.2M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.